Summit Therapeutics Inc.

US$16.33As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:SMMTHealthcare
Country USA
PE (Fwd) •••
TSR 10Y CAGR 3.32%
Div yield —
ROE (220.01%)
Biotechnology
Beta (5Y) (1.52)
PE TTM —
TSR TTM (13.64%)
Mkt cap US$13.06B
ROIC (136.65%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$20
19.50%
(62.44%)
Hold 6|0|6|0|6
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.20
0.20
0.19
0.21
20.37%
13.18%
2.59%
8.49%
Revenue$M
747.4
746.3
773.0
799.7
5.02%
1.45%
4.76%
6.69%
Peers (US$13.06B)
Cap (US$)
PE
11.43B
66.21x
Capital
TTM
5Y
10Y
Leveragex
1.992
0.935
0.715
EBIT/Intx
0.865
0.114
0.116
Own earn%
(41.29)
40.23
39.80
Sh yield%
39.70
11.55
13.29
Owners
Insiders/Inst%
1.11
89.94
Short interest%
2.58
SBC / revenue%
5.63
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
2
Op margin range%
24–27
$1 testx
0.0
Incr. ROIC%
1